Navigation Links
Second Ohio State cancer drug begins clinical trials testing
Date:6/18/2010

COLUMBUS, Ohio For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

This week, adult patients began receiving doses of the potentially groundbreaking drug, which is designed to treat relapsed or treatment-resistant multiple myeloma, chronic lymphocytic leukemia or lymphoma, said Dr. John Byrd, associate director of clinical translational research at OSUCCC-James and a leukemia specialist who initiated the drug's development with Ching-Shih Chen, an Ohio State cancer researcher and medicinal chemist.

The new phase I/IIa clinical trial will assess the safety and initial evidence of activity of the oral drug AR-42, which belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process. Ohio State is the only site worldwide accepting patients to the clinical trial, said Byrd.

"Early tests in cancer cell models showed that AR-42 is 10,000 fold more potent than the starting/parent agent," said Chen, a professor of pharmacy, urology and internal medicine who holds the Lucius A. Wing chair of cancer research.

In 2003, Byrd asked Chen to try to improve the potency of a short-chain fatty acid known to have a weak inhibitory effect against cancer growth. Chen worked with cancer center and pharmacy colleagues at Ohio State to develop the drug originally called OSU-HDAC42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC).

The agent has been licensed to the biopharmaceutical company Arno Therapeutics, Inc., for clinical development.

"It is exciting to see this very potent broad class I/II HDAC inhibitor enter the clinic for treatment of blood cancers and we look forward to generating meaningful clinical results from in this Phase I/IIa study," said Byrd. "We are incredibly grateful to organizations that have supported this effort to bring this drug forward to our blood cancer patients.

Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center and chief executive officer of the James Cancer Hospital and Solove Research Institute, praised the collaborative efforts of Ohio State researchers who worked more than 7 years to develop this drug.

"We are encouraged by its preclinical activity, and feel that this molecule could have meaningful clinical implications in a variety of cancers," said Caligiuri.

Dr. Michael Grever, chairman of the department of internal medicine at Ohio State and co-leader of the Experimental Therapeutics program at OSUCCC-James, was instrumental in moving this experimental agent from bench to bedside.


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. American Doctor Misses World Cycling Record by 4 minutes, 57 Seconds
2. Smoke-free air laws effective at protecting children from secondhand smoke
3. Second-line CML drugs evoke faster, better front-line remissions
4. Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
5. Career Training College, Pima Medical Institute, Offering Second Bachelor's Degree Program in Respiratory Therapy
6. BioConference Live Announces Speakers and Sponsors for Second Edition of Premier Online Conference for Life Science Community
7. Smoking Ups Risk of Second Breast Cancer
8. Cambridge Healthtech Institute to Host Its Second Annual Collaborative Innovation in Biomedicine Conference
9. Second volume of groundbreaking Emerging Model Organisms series is released
10. Second AGA Foundation/Bernard Lee Schwartz Foundation Research Scholar Award presented
11. Secondhand Smoke Boosts Sinusitis Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: